Persistent Benefit Of Vtd (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy For Multiple Myeloma: Long-Term Follow-Up Of A Randomized Phase 3 Pethema/Gem Study

Background: The randomized PETHEMA/GEM phase III trial GEM05menos65 (www.clinicaltrials.gov NCT00461747) demonstrated that pretransplant induction therapy with VTD resulted in a significantly higher CR rate both, pretransplant and postransplant and in a significantly longer progression-free survival (PFS) when compared with thalidomide/dexamethasone (TD) and combination chemotherapy plus bortezomib (VBMCP/VBAD/B) (Rosiñol et al, Blood 2012). We report here the long-term results of the trial, five years after the last patient was included.